ASAM MOUD/OTP Policy Update Coverage

Coverage Criteria and Medical Necessity

Covered with clinical-judgment-based criteria

ASAM supports coverage/approval when clinical judgment and specified documentation/conditions are met as follows:

Unsupervised Use — general: Allow unsupervised use of methadone based on treating practitioner's clinical judgment including at treatment entry; remove time-in-treatment and abstinence/toxicology absence requirements from unsupervised criteria.

ASAM applauds removing length-of-time-in-treatment and toxicology absence requirements and supports clinician judgment at entry

Methadone unsupervised supply schedule: From first 14 days: allow up to 7 days supply; from 31 days of treatment allow extended supplies — ASAM recommends permitting up to 30 days supply (instead of proposed 28 days), or otherwise the NPRM's 14 and 28 day tiers if not adopted.first 14 days: 7 days; from 31 days: ASAM recommends up to 30 days

Clinical rationale and documentation required for extended supplies

Telehealth initiation: Permit audio-visual telehealth for initial evaluation for Schedule II medications (methadone); permit audio-only for Schedule III (buprenorphine) but oppose audio-only for Schedule II; if audio-only for Schedule II is finalized, require clarification of 'in the presence of a licensed practitioner.'

ASAM supports telehealth with guardrails and opposes audio-only for Schedule II

Admission criteria: Permit OTP admission when patient meets diagnostic criteria for moderate or severe OUD, has OUD in remission, or is at high risk for recurrence/overdose; eliminate one-year duration requirement for OUD and remove the two documented unsuccessful attempts requirement for minors.

Supports broader access to OTPs and elimination of restrictive duration/prior-attempts rules

Initial dosing and formulation: Allow clinician to individualize initial methadone dosing above the typical initial 30 mg or total daily 40 mg threshold when documented with a specific rationale that 40 mg did not suppress withdrawal; permit oral methadone formulations (e.g., diskettes/tablets) that reduce parenteral misuse and allow formulation innovation.initial 30 mg or total daily 40 mg — documentation required if higher

Document specific clinical rationale for doses above thresholds

Admission and Initial Dosing

ASAM supports coverage when regulatory criteria are individualized and documented as follows:

OTP admission and dosing: Patient meets diagnostic criteria for moderate or severe OUD OR has OUD in remission OR is at high risk for recurrence or overdose; eliminate the one-year OUD duration requirement for OTP admission; remove the requirement for two documented unsuccessful attempts for individuals under 18; clinician may individualize initial methadone dosing above 40 mg if documented with a specific rationale that 40 mg did not suppress withdrawal.

References support clinician judgment and documentation requirements

Interim Treatment

Interim methadone treatment coverage notes:

Interim treatment period and eligibility: Support removing prohibition on unsupervised use for interim treatment and permit interim treatment when comprehensive services are not readily available; SAMHSA proposed extending interim period from 120 to 180 days — ASAM recommends extending interim treatment up to 360 days and removing limits to 'public or nonprofit, private' OTPs.NPRM: 120 -> proposed 180 days; ASAM recommends up to 360 days

ASAM cites workforce shortages and slow OTP expansion as rationale

Interim treatment continuity: Require documented plans for treatment continuation and transfer processes, and provision of crisis and ancillary services for interim treatment patients to support continuity of care.

ASAM supports proposed requirements for transfers and documented continuation plans

Confined Settings / Long-term Care Facilities

Access to MOUD in confined settings where medically necessary:

Provision in confined settings: Include local jails and state/federal prisons in the definition of long-term care facilities eligible to provide MOUD without separate OTP certification for patients admitted for primary medical conditions other than OUD; recognize that facilities registered with the DEA as 'hospital/clinic' need not obtain separate 21 U.S.C. 823(h) registration to treat admitted patients; ensure final rule acknowledges patients may be admitted for reasons other than OUD treatment.

ASAM frames inclusion as correcting an omission and protecting rights to medically necessary care

Practitioner Training and Qualifications

Practitioner qualifications and training for OTPs:

Medical director qualifications: Require the medical director to have completed an accredited residency and at least 1 year of experience in addiction medicine or addiction psychiatry; board certification in primary specialty and in addiction medicine/psychiatry is strongly preferred; ensure OTP practitioners maintain licensure/certification.

ASAM requests codifying training/experience requirements in regulation rather than guidance

Care Integration and Dispensing

Integration with non-OTP providers and community pharmacies:

Non-OTP practitioner roles and transitions: Allow non-OTP practitioners, with documented agreements with OTPs, to perform the required initial medical examination (screening and full exam) and permit treatment to commence after the screening exam is completed, assuming no contraindications, to facilitate timely transitions and continuity of MOUD.

Aims to reduce siloing and improve transitions across settings

Community pharmacy dispensing safeguards: Support exploring dispensing methadone from community pharmacy stock provided safeguards are met: OTP remains certified, community pharmacies comply with Attorney General standards for security and recordkeeping or obtain necessary Attorney General exceptions, and OTPs ensure appropriate oversight.

ASAM recommends pharmacy dispensing only with security/recordkeeping safeguards and proper OTP qualification

ASAM recommends explicitly clarifying that the unsupervised use criteria in §8.12(i)(2) should not be applied to buprenorphine and buprenorphine products. The comment explains that most buprenorphine is prescribed and dispensed in office-based settings and at community pharmacies, that the CAA 2023 removed x‑waiver limits, and that excluding buprenorphine from the §8.12(i)(2) unsupervised-use requirements would align OTP rules with how buprenorphine is handled in other medical settings.

ASAM urges removal of the limiting phrase "public or nonprofit, private" from the interim treatment provisions and recommends deleting redundant statutory cross‑references in §8.12(j)(1). ASAM also recommends extending the interim treatment period (discussed elsewhere) and notes that removing the restrictive phrase and redundant language would avoid unnecessary barriers to providing interim methadone treatment while programs expand capacity.

The cited excerpts do not propose explicit coverage exclusions. Instead, they discuss administrative‑law concepts such as the logical outgrowth doctrine and summarize literature on methadone‑involved overdoses and OTP census trends to inform rulemaking. ASAM’s comments therefore focus on foreseeable legal and evidentiary implications of regulatory choices rather than on identifying categorical coverage exclusions.

ASAM supports integration of harm reduction and recovery support services into OTP care plans and the definition of comprehensive treatment, and explicitly endorses the proposed provision that patient refusal of counseling shall not preclude receiving MOUD. This means counseling refusal should not be used as a basis to deny medication for opioid use disorder, and programs should still offer evidence‑based harm‑reduction interventions and linkage services as part of patient‑centered care.

Within the provided excerpts, ASAM does not identify or assert any statements declaring MOUD or OTP services to be not medically necessary. The document instead emphasizes the evidence base for MOUD and discusses study limitations and policy effects, without framing services as excluded from medical necessity coverage.

Provider Actions, Documentation, and Operational Requirements

Prior Authorization

Prior Authorization — not specified

Prior authorization: Not specified in the excerpts. The source materials do not state any payer prior authorization requirements for methadone or MOUD in OTPs or community pharmacy dispensing; providers should not assume prior authorization processes from these regulatory excerpts but must follow payer-specific rules if present.

No prior authorization language present in proposed §8.11/§8.12 excerpts

Denial Risk

Unsupervised use criteria enforcement — document clinical judgment and patient education

Enforcement of unsupervised use criteria: the NPRM and ASAM commentary remove certain time-in-treatment and toxicology prerequisites and emphasize clinical judgment for unsupervised use. However, restrictive language or inconsistent terminology ("take home" vs "unsupervised") could create enforcement ambiguity and potential denial risk if programs cannot document adherence to the finalized rule. Programs must be prepared to document clinical justification when granting unsupervised supplies and to demonstrate safe storage/transport education.

Level of Care and Program Definitions

OTP / Medication for OUD

(Informational): ASAM recommends clarifying that unsupervised use criteria in §8.12(i)(2) should not apply to buprenorphine and buprenorphine products.

Policy clarification request

OTP / Interim Treatment / Integration with other settings

Interim treatment integration: Support permitting interim treatment when comprehensive services are not readily available and require documented plans for continuity; recommend clarifying that non-OTP settings may perform initial exams to facilitate transitions into OTP care.

Links interim treatment policy to cross-setting transitions

Opioid Treatment Program / Methadone treatment (discussion)

MOUD Treatment Modalities and OTP Services

MOUD (methadone, buprenorphine) and OTP services — 3 top-level nodes

3 top-level coverage positions for MOUD and OTP services:

Telehealth for MOUD initiation: Permit telehealth (audio-visual) for the two-part initial examination for methadone; support audio-only telehealth for buprenorphine (Schedule III) but oppose audio-only for Schedule II.

ASAM supports telehealth with specific guardrails

Harm reduction & integrated services: Integrate harm reduction and recovery support services, including counseling, overdose education, testing and linkage for HCV/HIV/STIs, and universal/opt-out HCV screening as part of initial assessment; patient refusal of counseling should not preclude MOUD.

Supports multimodal, patient-centered care and public health screening

Split dosing for pregnancy: Allow split dosing of methadone for pregnant patients when clinically appropriate without requiring additional laboratory proof or administrative exceptions; respect patients' right to refuse pregnancy testing without losing services.

Visit Limits and Unsupervised Take-Home Supply

inv-36: unsupervised methadone supply — up to 30 days supply

ASAM recommended unsupervised supplyFrom 31 days of treatment, permit up to 30 days' supply of methadone for unsupervised use (in lieu of the NPRM's 28 days).

Proposed NPRM first 14 daysDuring the first 14 days of treatment the NPRM proposes 7 days of unsupervised supply.

NPRM later-treatment comparisonNPRM proposed 14 days from 31 days of treatment and 28 days thereafter (ASAM recommends 30 days instead of 28).

inv-37: unsupervised methadone supply — 7 days

NPRM proposal for early treatmentDuring the first 14 days of treatment, the NPRM proposes permitting 7 days of methadone for unsupervised use.

ASAM context noteASAM acknowledges this 7-day proposal while recommending alignment to broader schedules used for other Schedule II medications after stabilization.

Key Definitions

inv-25: Medication unit definition

DefinitionMedication unit: an entity established as part of, but geographically separate from, an OTP that can dispense or administer MOUD, collect samples for drug testing or analysis, or provide other OTP services; can be brick-and-mortar or mobile.

StaffingMedication units may use appropriate, licensed OTP practitioners, contractors working on behalf of the OTP, or community pharmacists to provide services.

Scope of servicesMedication units can offer any services that are provided in an OTP, assuming compliance with applicable Federal, State, and local law and appropriate privacy and space.

inv-26: Unsupervised use / take-homes definition

Statutory term vs. technology'Unsupervised use' is the statutory term (21 U.S.C. 823(h)); ASAM notes that 'take home' and 'unsupervised' are not synonymous because technologies can enable supervised remote use.

Background and Evidence

MOUD — including methadone and buprenorphine — is supported by evidence showing reductions in illicit opioid use, overdose risk, and infectious‑disease transmission, and improved retention in care. ASAM’s comments reference literature on methadone‑involved overdose trends surrounding the 2020 regulatory flexibilities and note study limitations while arguing that expanded unsupervised use and telehealth during the COVID‑19 public health emergency increased access with limited evidence of diversion. These summaries are offered to support regulatory changes that prioritize clinician judgment, harm reduction, and broader access to life‑saving MOUD.

OpenPayer

ASAM comments on SAMHSA NPRM for MOUD/OTP regulations